Clarification of how HIV-1 DNA and protein immunizations may be better used to obtain HIV-1-specific mucosal and systemic immunity

References

• Zhang Z-O, Schuler T, Zupanic M et al. Sexual transmission and propagation of SIV and HIV in resting and activated cells. Science286, 1353–1357 (1999).
   PubMed Web of Science ®Google Scholar
• Achievements in public health 1900–1999. Control of infectious diseases. Morb. Mortal. Wkly. Rep.48, 621–628 (1999).
   PubMedGoogle Scholar
• Crotty S, Andino R. Poliovirus vaccine strains as mucosal vaccine vectors and their potential use to develop an AIDS vaccine. Adv. Drug Deliv. Rev.56, 835–852 (2004).
   PubMed Web of Science ®Google Scholar
• Crotty S, Lohman BL, Lu FX, Tang S, Miller CJ, Andino R. Mucosal immunization of cynomolgus macaques with two serotypes of live poliovirus vectors expressing simian immunodeficiency virus antigens: stimulation of humoral, mucosal, and cellular immunity. J.Virol.73, 9485–9495 (1999).
   PubMed Web of Science ®Google Scholar
• Crotty S, Miller CJ, Lohman BL et al. Protection against simian immunodeficiency virus vaginal challenge by using Sabin poliovirus vector. J.Virol.75, 7435–7452 (2001).
   PubMed Web of Science ®Google Scholar
• Heeney J, Åkerblom L, Barnett S et al. HIV-1 vaccine-induced immune responses which correlate with protection from SHIV infection: compiled preclinical efficacy data from trials with ten different HIV-1 vaccine candidates. Immunol. Lett.66, 189–195 (1999).
   PubMed Web of Science ®Google Scholar
• Mascola JR, Stiegler G, Van Cott TC et al. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat. Med.6, 207–211 (2000).
   PubMed Web of Science ®Google Scholar
• Baba TW, Liska V, Hofmann-Lehmann R et al. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian–human immunodeficiency virus infection. Nat. Med.6, 200–206 (2000).
   PubMed Web of Science ®Google Scholar
• Parren PHI, Marx PA, Hessell AJ et al. Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J.Virol.75, 8340–8347 (2001).
   PubMed Web of Science ®Google Scholar
• Mazzoli S, Trabattoni D, Lo Caputo L et al. HIV-specific mucosal and cellular immunity in HIV-seronegative partners of HIV-seropositive individuals. Nat. Med.3, 1250–1256 (1997).
   PubMed Web of Science ®Google Scholar
• Kaul R, Rowland-Jones SL, Kimani J et al. New insights into HIV-1 specific cytotoxic T-lymphocyte responses in exposed, persistently seronegative Kenyan sex workers. Immunol. Lett.79, 3–13 (2001).
   PubMed Web of Science ®Google Scholar
• Devito C, Broliden K, Kaul R et al. Mucosal and plasma IgA from HIV-1 exposed uninfected individuals inhibit HIV-1 transcytosis across human epithelial cells. J. Immunol.165, 5170–5176 (2000).
   PubMed Web of Science ®Google Scholar
• Brandtzaeg P. Role of secretory antibodies in the defence against infections. Int. J. Med. Microbiol.293, 3–15 (2003).
   PubMed Web of Science ®Google Scholar
• Mäkitalo B, Lundholm P, Hinkula J et al. Enhanced cellular immunity and systemic control of SHIV infection by combined parenteral and mucosal administration of a DNA prime MVA boost vaccine regimen. J. Gen. Virol.85, 2407–2418 (2004).
   PubMed Web of Science ®Google Scholar
• Stolte-Leeb N, Sauermann U, Norley S et al. Sustained conservation of CD4+ T cells in multiprotein triple modality-immunized rhesus macaques after intrarectal challenge with simian immunodeficiency virus. Viral Immun.19, 448–457 (2006).
   PubMed Web of Science ®Google Scholar
• Lehner T, Wang Y, Cranage M et al. Protective mucosal immunity elicited by targeted iliac lymph node immunization with a subunit SIV envelope and core vaccine in macaques. Nat. Med.2, 767–775 (1996).
   PubMed Web of Science ®Google Scholar
• Belyakov IM, Kelsall HZ, Kutznetsov VA et al. Mucosal AIDS vaccine reduces disease and viral load in gut reservoir and blood after mucosal infection of macaques. Nat. Med.7, 1320–1326 (2001).
   PubMed Web of Science ®Google Scholar
• Levy JA, Mackewikz CE, Barker E. Controlling HIV pathogenesis: the role of the noncytotoxic anti-HIV response of CD8+ T cells. Immunol. Today17, 217–224 (1996).
   PubMedGoogle Scholar
• Kaul R, Plummer FA, Kimani J et al. HIV-1 specific mucosal CD8+ lymphocyte responses in the cervix of HIV-1-resistant prostitutes in Nairobi. J. Immunol.164, 1602–1611 (2000).
   PubMed Web of Science ®Google Scholar
• Ferrari G, Humphrey W, McElrath MJ et al. Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T-lymphocyte reactivities in uninfected volunteers. Proc. Natl Acad. Sci. USA94, 1396–1401 (1997).
   PubMed Web of Science ®Google Scholar
• Shriver JW, Fu TM, Chen L et al. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature415, 331–335 (2002).
   PubMed Web of Science ®Google Scholar
• Musey L, Hughes J, Schacker T, Shea T, Corey L, McElrath MJ. Cytotoxic T-cells, viral load, and disease progression in early human immunodeficiency virus type 1 infection. N. Engl. J. Med.337, 1267–1274 (1997).
   PubMed Web of Science ®Google Scholar
• Lehner T, Mitchell E, Bergmeier L et al. The role of γδ T cells in generating antiviral factors and β-chemokines in protection against mucosal simian immunodeficiency virus infection. Eur. J. Immunol.30, 2245–2256 (2000).
   PubMed Web of Science ®Google Scholar
• Planz O, Ehl S, Furrer E et al. A critical role for neutralizing-antibody-producing B-cells, CD4(+) T cells and interferon in persistent and acute infection of mice with lymphochoriomenengitis virus. Proc. Natl Acad. Sci. USA94, 6874–6879 (1997).
   PubMed Web of Science ®Google Scholar
• Johansson EL, Wassen L, Holmgren J, Jertborn M, Rudin A. Nasal and vaginal vaccinations have differential effects on antibody responses in vaginal and cervical secretions in humans. Infect. Immun.69, 7481–7486 (2001).
   PubMed Web of Science ®Google Scholar
• Brandtzaeg P, Johansen F-E. Mucosal B-cells: phenotypic characteristics, transcriptional regulation, and homing properties. Immunol. Rev.206, 32–63 (2005).
   PubMed Web of Science ®Google Scholar
• Holmgren J, Czerkinsky C. Mucosal immunity and vaccines. Nat. Med.4, S45–S53 (2005).
   Google Scholar
• Wallace M, Bartz SR, Chang WL, Mackenzie DA, Pauza CD, Malkovsky M. γ δ T lymphocyte responses in HIV. Clin. Exp. Immunol.103, 177–184 (1996).
   PubMed Web of Science ®Google Scholar
• Nag P, Kim J, Sapiega V et al. Women with cervicovaginal antibody-dependent cell-mediated cytotoxicity have lower genital HIV-1 RNA loads. J. Infect. Dis.190, 1970–1978 (2004).
   PubMed Web of Science ®Google Scholar
• Douek DC, Picker LJ, Koup RA. T cell dymanics in HIV-1 infection. Annu. Rev. Immunol.21, 265–304 (2003).
   PubMed Web of Science ®Google Scholar
• Kiyono H, Fukuyama S. NALT- versus Peyers patch mediated mucosal immunity. Nat. Rev. Immunol.4, 699–710 (2004).
   PubMed Web of Science ®Google Scholar
• Staats HF, Bradney CP, Gwinn WM et al. Cytokine requirements for induction of systemic and mucosal CTL after nasal immunization. J. Immunol.167, 5386–5394 (2001).
   PubMed Web of Science ®Google Scholar
• Johansson EL, Bergqvist C, Edebo A, Johansson C, Svennerholm AM. Comparison of different routes of vaccination for eliciting antibody responses in the human stomach. Vaccine22, 984–990 (2004).
   PubMed Web of Science ®Google Scholar
• Holmgren J, Adamsson J, Anjuere F et al. Mucosal adjuvants and anti-infection and anti-immunopathology vaccines based on cholera toxin, cholera toxin B subunit and CpG DNA. Immunol. Lett.97, 181–188 (2005).
   PubMed Web of Science ®Google Scholar
• Kozlowski PA, Cu-Uvin S, Neutra MR, Flanigan TP. Comparison of the oral, rectal, and vaginal immunization routes for induction of antibodies in rectal and genital tract secretions of women. Infect. Immun.65, 1387–1394 (1997).
   PubMed Web of Science ®Google Scholar
• Klavinskis LS, Gao L, Barnfield C, Lehner T, Parker S. Mucosal immunization with DNA-liposome complexes. Vaccine15, 818–820 (1997).
   PubMed Web of Science ®Google Scholar
• Jertborn M, Nordstrom I, Kilander A, Czerkinsky C, Holmgren J. Local and systemic immune responses to rectal administration of recombinant cholera toxin B subunit in humans. Infect. Immun.69, 4125–4128 (2001).
   PubMed Web of Science ®Google Scholar
• Gockel CM, Bao S, Beagley KW. Transcutaneous immunization induces mucosal and systemic immunity: a potent method for targeting immunity to the female reproductive tract. Mol. Immunol.37, 537–544 (2000).
   PubMed Web of Science ®Google Scholar
• Anjuere F, George-Chandy A, Audant F, Rosseau D, Holmgren J, Czerkinsky C. Transcutaneous immunization with cholera toxin B subunit adjuvant suppresses IgE antibody responses via selective induction of Th1 immune responses. J. Immunol.170, 5103–5111 (2003).
   PubMed Web of Science ®Google Scholar
• Enioutina EY. The induction of systemic and mucosal immune responses to antigen-adjuvant compositions administered into the skin: alterations in the migratory properties of dendritic cells appears important for stimulating mucosal immunity. Vaccine18, 2753–2767 (2000).
   PubMed Web of Science ®Google Scholar
• Kozlowski PA, Williams SB, Lynch RM et al. Differential induction of mucosal and systemic antibody responses in women after nasal, rectal, or vaginal immunization: influence of the menstrual cycle. J. Immunol.169, 566–574 (2002).
   PubMed Web of Science ®Google Scholar
• Broliden K, Hinkula J, Devito C et al. Functional HIV-1 specific IgA antibodies in HIV-1 exposed, persistently IgG seronegative female sexworkers. Immunol. Lett.79, 29–36 (2001).
   PubMed Web of Science ®Google Scholar
• Yang ZY, Wyatt LS, Kong WP, Moodie Z, Moss B, Nabel GJ. Overcoming immunity to a viral vaccine by DNA priming before vector boosting. J. Virol.77, 799–803 (2003).
   PubMed Web of Science ®Google Scholar
• Belyakov IM, Derby MA, Ahlers JD et al. Mucosal immunization with HIV-1 peptide vaccine induces mucosal and systemic cytotoxic T lymphocytes and protective immunity in mice against intrarectal recombinant HIV-1 vaccinia challenge. Proc. Natl Acad. Sci. USA95, 1709–1714 (1998).
   PubMed Web of Science ®Google Scholar
• Koff W, Johnson PR, Watkins DI et al. HIV vaccine design: insights from live attenuated SIV vaccines. Nat. Immun.7, 19–23 (2006).
   Google Scholar
• Mazzoli S, Trabattoni D, Lo Caputo S et al. HIV-1 specific mucosal and cellular immunity in HIV-seronegative partners of HIV-seropositive individuals. Nat. Med.3, 1250–1257 (1997).
   PubMed Web of Science ®Google Scholar
• Kaul R, Plummer FA, Kimani J et al. HIV-1 specific mucosal CD8+ lymphocyte responses in the cervix of HIV-1-resistant Kenyan sexworkers. AIDS13, 29–34 (2000).
   Google Scholar
• Burton DR, Stanfield RL, Wilson IA. Antibody vs. HIV in a clash of evolutionary titans. Proc. Natl Acad. Sci. USA102, 14943–14948 (2005).
   PubMed Web of Science ®Google Scholar
• Bergquist C, Johansson EL, Lagergard T, Holmgren J, Rudin A. Intranasal vaccination of humans with recombinant cholera toxin B subunit induces systemic and local antibody responses in the upper respiratory tract and the vagina. Infect. Immun.65, 2676–2684 (1997).
   PubMed Web of Science ®Google Scholar
• Belyakov IM, Kutznetsov VA, Kelsal B et al. Impact of vaccine induced mucosal high-avidity CD8+ CTLs delay of AIDS viral dissemination from mucosa. Blood107, 3258–3264 (2006).
   PubMed Web of Science ®Google Scholar
• Belyakov IM, Hammond SA, Ahlers JD, Glenn GM, Berzofsky JA. Transcutaneous immunization induces mucosal CTLs and protective immunity by migration of primed skin dendritic cells. J. Clin. Invest.113, 998–1007 (2004).
   PubMed Web of Science ®Google Scholar
• Bomsel M, David V. Mucosal gatekeepers: selecting HIV viruses for early infection. Nat. Med.8, 114–116 (2002).
   PubMed Web of Science ®Google Scholar
• Kindberg E, Hejdeman B, Bratt G et al. A nonsense mutation (428G-A) in the fucosyltransferase FUT-2 gene affects the progression of HIV-1 infection. AIDS20, 685–689 (2006).
   PubMed Web of Science ®Google Scholar
• Alfsen A, Iniguez P, Bouguyon E, Bomsel M. Secretory IgA specific for a conserved epitope on gp41 envelope glycoprotein inhibits epithelial transcytosis of HIV-1. J. Immunol.166, 6257–6265 (2001).
   PubMed Web of Science ®Google Scholar
• Matoba N, Magerus A, Geyer BC et al. A mucosally targeted subunit vaccine candidate elicit HIV-1 transcytosis-blocking Abs. Proc. Natl Acad. Sci. USA101, 13584–13589 (2004).
   PubMed Web of Science ®Google Scholar
• Burton DR, Desrosier RC, Doms RW et al. HIV vaccine design and the neutralizing antibody problem. Nat. Immunol.5, 233–236 (2004).
   PubMed Web of Science ®Google Scholar
• Slobod KS, Bonsignori M, Brown SA, Xiaoyan Z, Stambas J, Hurwitz JL. HIV vaccines: brief review and discussion of future directions. Expert Rev. Vaccines4(3), 305–313 (2005).
   PubMed Web of Science ®Google Scholar
• Wahren B, Liu M. Therapeutic vaccination against HIV. Expert Rev. Vaccines3(4), S179–S188 (2004).
   PubMed Web of Science ®Google Scholar
• Liu MA, Ulmer JB. Human clinical trials of plasmid DNA vaccines. Adv. Genet.55, 25–40 (2005).
   PubMed Web of Science ®Google Scholar
• Berzofsky JA, Ahlers JD, Derby MA, Pendelton CD, Archi T, Belyakov IM. Approaches to improve engineered vaccines for human immunodeficiency virus and other viruses that cause chronic infections. Immunol. Rev.170, 151–172 (1999).
   PubMed Web of Science ®Google Scholar
• Belyakov IM, Wyatt LS, Ahlers JD et al. Induction of a mucosal cytotoxic T lymphocyte response by intrarectal immunization with a replication deficient recombinant vaccinia virus expressing human immunodeficiency virus 89.6 envelope protein. J. Virol.72, 8264–8272 (1998).
   PubMed Web of Science ®Google Scholar
• Hill AV. DNA-based vaccines for malaria: a heterologous prime-boost immunization strategy. Dev. Biol. (Basel)104, 171–179 (2000).
   PubMedGoogle Scholar
• Moorthy VS, Pinder M, Reece WH et al. Safety of DNA and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers. Vaccine21, 2004–2011 (2003).
   Web of Science ®Google Scholar
• Eo SK, Gierybska M, Kamar AA, Rouse BT. Prime–boost immunization with DNA-vaccine: mucosal route of administration changes the rules. J. Immunol.166, 5473–5479 (2001).
   PubMed Web of Science ®Google Scholar
• Amara RR, Ibegbu C, Villinger F et al. Control of mucosal challenge and prevention of AIDS by multiprotein DNA/MVA vaccine. Science292, 69–74 (2001).
   PubMed Web of Science ®Google Scholar
• Vajdy M, Singh M, Kazzaz J et al. Mucosal and systemic anti-HIV responses in rhesus macaques following combinations of intranasal and parenteral immunizations. AIDS Res. Hum. Retrov.20, 1269–1281 (2004).
   PubMed Web of Science ®Google Scholar
• Belyakov IM, Berzofsky JA. Immunobiology of mucosal HIV infection and the basis for the development of a new generation of mucosal AIDS vaccines. Immunity20, 247–253 (2004).
   PubMed Web of Science ®Google Scholar
• van Baalen CA, Pontesilli O, Huisman RC et al. Human immunodeficiency virus type 1 Rev- and Tat-specific cytotoxic T-cell frequencies inversely correlate with rapid progression to AIDS. J. Gen. Virol.78, 1913–1918 (1997).
   PubMed Web of Science ®Google Scholar
• Rollman E, Bråve A, Boberg A et al. The rationale behind a vaccine based on multiple HIV antigens. Microbes Infect.7, 1414–1423 (2005).
   PubMed Web of Science ®Google Scholar
• Hinkula J, Rollman E, Benthin R, Wahren B. Genetic immunization with multiple HIV-1 genes provides protection against HIV-1/MuLV pseudovirus challenge in vivo. Cells Tissues Organs177, 169–184 (2004).
   PubMed Web of Science ®Google Scholar
• Devito C, Zuber B, Schröder U et al. Intranasal HIV-1-gp160-DNA/gp41 peptide prime–boost immunization regimen results in long-term HIV-1 neutralizing humoral mucosal and systemic immunity. J. Immunol.173, 7078–7089 (2004).
   PubMed Web of Science ®Google Scholar
• Hinkula J, Devito C, Zuber B et al. A novel DNA adjuvant, N3, enhances mucosal and systemic immune responses induced by HIV-1 DNA and peptide immunizations. Vaccine24, 4494–4497 (2006).
   PubMed Web of Science ®Google Scholar
• Spetz A-L, Smed Sörensen A, Patterson BK et al. Induction of HIV-1 specific immunity in mice after vaccination with apoptotic bodies from HIV-1/murine leukemia virus infected cells. J. Immunol.169, 5771–5779 (2002).
   PubMed Web of Science ®Google Scholar
• HogenEsch H. Mechanisms of stimulation of the immune response by aluminium adjuvants. Vaccine20, S34–S39 (2002).
   PubMed Web of Science ®Google Scholar
• Krieg AM, Yi AK, Matson S et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature374, 546–549 (1995).
   PubMed Web of Science ®Google Scholar
• Jiang JO, Patrick A, Moss RB, Rosenthal K. CD8+ T cell mediated cross-clade protection in the genital tract following intranasal immunity with inactivated human immunodeficiency virus antigen plus CpG oligonucleotides. J. Virol.79, 393–400 (2005).
   PubMed Web of Science ®Google Scholar
• Agrawal S, Kandimalla ER. Medicinal chemistry and therapeutic potential of CpG DNA. Trends Mol. Med.8, 114–121 (2002).
   PubMed Web of Science ®Google Scholar
• Stevcevaa L, Ferrari MG. Mucosal adjuvants. Curr. Pharm. Des.11, 801–811 (2005).
   PubMed Web of Science ®Google Scholar
• Ryan E, Daly LM, Mills HG. Immuneregulators and delivery systems for vaccination by mucosal routes. Trends Biotech.19, 293–304 (2001).
   PubMed Web of Science ®Google Scholar
• Clements CJ, Wesselingh SL. Vaccine presentations and delivery technologies – what does the future hold ? Expert Rev. Vaccines4(3), 281–287 (2005).
   PubMed Web of Science ®Google Scholar
• Applequist SE, Rollman E, Wareing MD et al. Activation of innate immunity, inflammation, and potentiation of DNA vaccination through mammalian expression of the TLR5 agonist flagellin. J. Immunol.175, 3882–3891 (2005).
   PubMed Web of Science ®Google Scholar
• Kjerrström-Zuber A, Bråve A, Engström G et al. Topical administration of imiquimod as a novel adjuvant for human immunodeficiency virus (HIV) DNA. Vaccine22, 1791–1798 (2004).
   PubMed Web of Science ®Google Scholar
• Dubensky TW, Liu MA, Ulmer JB. Delivery systems for gene-based vaccines. Mol. Med.6, 723–732 (2000).
   PubMed Web of Science ®Google Scholar
• Fuller DH, Rajkumar PA, Wilson LA et al. Induction of mucosal protection against primary, heterologous simian immunodeficiency virus by DNA vaccine. J.Virol.76, 3309–3317 (2002).
   PubMed Web of Science ®Google Scholar
• Schadeck EB, Sidhu M, Egan MA et al. A dose sparing effect by plasmid encoded IL-12 adjuvant on a SIVgag-plasmid DNA vaccine in rhesus macaques. Vaccine24, 4677–4687 (2006).
   PubMed Web of Science ®Google Scholar
• Bertley FMN, Kozlowski PA, Wang S-W et al. Control of simian/human immunodeficiency virus viremia and disease progression after IL-2-augmented DNA-modified vaccinia virus Ankara nasal vaccination in nonhuman primates. J. Immunol.172, 3745–3757 (2004).
   PubMed Web of Science ®Google Scholar
• Neutra MR, Kozlowski PA. Mucosal vaccines: the promise and the challenge. Nat. Rev. Immunol.6, 148–158 (2006).
   PubMed Web of Science ®Google Scholar
• Fomsgaard A. HIV-1 DNA vaccines. Immunol. Lett.65, 127–131 (1999).
   PubMed Web of Science ®Google Scholar
• Lehner T, Hoelscher M, Clerici M et al. European Union and EDCTP strategy in the global context: recommendations for preventive HIV/AIDS vaccines research. Vaccine23, 5551–5556 (2005).
   PubMed Web of Science ®Google Scholar
• D’Souza MP, Cairns JS, Plaeger SF. Current evidence and future directions for targeting HIV entry: therapeutic and prophylactic strategies. JAMA284, 215–222 (2000).
   PubMed Web of Science ®Google Scholar
• Wu L, Kong W, Nabel GJ. Enhanced breath of CD4 T-cell immunity by DNA prime and adenovirus boost immunization to human immunodeficiency virus Env and Gag immunogens. J. Virol.79, 8024–8031 (2005).
   PubMed Web of Science ®Google Scholar
• Donelly JJ, Wahren B, Liu MA. DNA vaccines: progress and challenges. J. Immunol.175, 633–639 (2005).
   PubMed Web of Science ®Google Scholar
• Rowcliffe E. N-linked glycosylation of HIV-1 and Hantaan virus glycoproteins: implications for vaccination and therapy. Doctoral thesis Göteborg University, Sweden (2006).
   Google Scholar
• Berzofsky JA, Ahlers JD, Belyakov IM. Strategies for designing and optimizing new generation vaccines. Nat. Rev. Immunol.1, 209–219 (2001).
   PubMed Web of Science ®Google Scholar
• Letvin NL, Huang Y, Chakrabarti BK et al. Heterologous envelope immunogens contribute to AIDS vaccine protection in rhesus macaques. J.Virol.78, 7490–7497 (2004).
   PubMed Web of Science ®Google Scholar
• Kent SJ, Dale CJ, Ranasinghe C et al. Mucosally administered human-simian immunodeficiency virus DNA and fowlpoxvirus-based recombinant vaccines reduce acute phase viral replication in macaques following vaginal challenge with CCR5-tropic SHIVSF162P3. Vaccine23, 5009–5021 (2005).
   PubMed Web of Science ®Google Scholar
• Goonetilleke N, Moore S, Dally L et al. Induction of multifunctional human immunodeficiency virus type 1 (HIV-1)-specific T cells capable of proliferation in healthy subjects by using a prime-boost regimen of DNA and modified vaccinia virus Ankara-vectored vaccines expressing HIV-1 gag coupled to CD8+ T-cell epitopes. J.Virol.80, 4717–4728 (2006).
   PubMed Web of Science ®Google Scholar
• McConkey SJ, Reece WH, Moorthy VS et al. Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. Nat. Med.9, 729–735 (2003).
   PubMed Web of Science ®Google Scholar
• Boyer JD, Cohen AD, Vogt S et al. Vaccination of seronegative volunteers with a human immunodeficiency virus type 1 env/rev DNA vaccine induces antigen-specific proliferation and lymphocyte production of β-chemokines. J. Infect. Dis.181, 476–483 (2000).
   PubMed Web of Science ®Google Scholar
• Asakura Y, Lundholm P, Kjerrström AK et al. DNA-plasmids of HIV-1 induce systemic and mucosal immune responses. Biol. Chem.380, 375–379 (1999).
   PubMed Web of Science ®Google Scholar
• Lundholm P, Asakura Y, Hinkula J, Lucht E, Wahren B. Induction of mucosal IgA by a novel jet delivery technique for HIV-1 DNA. Vaccine17, 2036–2042 (1999).
   PubMed Web of Science ®Google Scholar
• Rowcliffe E, Bolmstedt A, Biller A, Wahren B, Olofsson S, Hinkula J. Demonstration of neutralizing mucosal IgA response to intranasal HIV-1 env DNA vaccines with or without the V3 glycosylation site. Scand. J. Infect. Dis.36, 360–364 (2004).
   PubMed Web of Science ®Google Scholar
• Rollman E, Ljungberg K, Hinkula J, Liu M, Wahren B. Multi-subtype gp160 DNA immunization induces broadly neutralizing anti-HIV antibodies. Gene Ther.11, 1146–1154 (2004).
   PubMed Web of Science ®Google Scholar
• Zuber B, Hinkula J, Vodros D et al. Induction of immune responses and break of tolerance by DNA against the HIV-1 coreceptor CCR5 but no protection from SIVsm challenge. Virology20, 400–411 (2000).
   Google Scholar
• Wang SW, Kalyanarman VS, Nair BC et al. Effective induction of simian immunodeficiency virus-specific systemic and mucosal immune responses in primates by vaccination with proviral DNA producing intact but non-infectious virions. J.Virol.74, 10514–10522 (2000).
   PubMed Web of Science ®Google Scholar
• Negri DR, Baroncelli S, Catone S et al. Protective efficacy of a multicomponent vector vaccine in cynomolgus monkeys after intrarectal simian immunodeficiency virus challenge. J. Gen. Virol.85, 1191–1201 (2004).
   PubMed Web of Science ®Google Scholar
• Lundholm P, Leandersson AC, Christensson B, Bratt G, Sandström E, Wahren B. DNA mucosal HIV vaccine in humans. Virus Res.82, 141–145 (2002).
   PubMed Web of Science ®Google Scholar
• Cebere I, Dorrell L, McShane H et al. Phase I clinical trial safety of DNA- and modified virus Ankara-vectored human immunodeficiency virus type 1 (HIV-1) vaccines administered alone and in a prime–boost regime to healthy HIV-1-uninfected volunteers. Vaccine24, 417–425 (2006).
   PubMed Web of Science ®Google Scholar
• Clerici M, Barassi C, Devito C et al. Serum IgA of HIV-exposed uninfected individuals inhibit HIV through recognition of a region within the α-helic of gp41. AIDS6, 1731–1741 (2002).
   Google Scholar
• Hanke T, McMichael AJ. Design and construction of an experimental HIV-1 vaccine for a year-2000 clinical trial in Kenya. Nat. Med.6, 951–955 (2000).
   PubMed Web of Science ®Google Scholar
• Srinivas SR, Gomez P, Mascola JR et al. Comparative evaluation of three different intramuscular delivery methods for DNA immunization in a nonhuman primate animal model. Vaccine24, 367–373 (2006).
   PubMed Web of Science ®Google Scholar
• Buonaguro L, Visciano ML, Tornesello ML, Tagliamonte M, Biryahwaho B, Buonaguro FM. Induction of systemic and mucosal cross-clade nautralizing antibodies in Balb/c mice immunized with human immunodeficiency virus type 1 clade A virus-like particles administered by different routes of inoculation. J. Virol.79, 7059–7067 (2005).
   PubMed Web of Science ®Google Scholar
• Belec L, Ghys PD, Hocini H et al. Cervicovaginal secretory antibodies to human immunodeficiency virus type 1 (HIV-1) that block viral transcytosis through tight epithelial barriers in highly exposed HIV-1-seronegative African women. J. Infect. Dis.184, 1412–1422 (2001).
   PubMed Web of Science ®Google Scholar